Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPLAND: CIL001 for Cochlear Synaptopathy in Type 2 Diabetes
NCT07472907Phase 2Not yet recruiting
- Sponsor
- Cilcare
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of paliroden in cochlear synaptopathy (CS), sponsored by Cilcare. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
paliroden
03
Conditions
cochlear synaptopathy (CS)
Beyond the preview
Go deeper on NCT07472907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472907.